Search results
Results from the WOW.Com Content Network
Attention deficit hyperactivity disorder management options are evidence-based practices with established treatment efficacy for ADHD.Approaches that have been evaluated in the management of ADHD symptoms include FDA-approved pharmacologic treatment and other pharmaceutical agents, psychological or behavioral approaches, combined pharmacological and behavioral approaches, cognitive training ...
Stimulant medications and certain therapies are more effective in treating ADHD symptoms than placebos, a new study on more than 14,000 adults has found.
These include issues around the governance of the therapy, whether treatment should be available only to those who can afford it, and whether the availability of treatment creates a stigma for those with color blindness. Given the large number of people with color blindness, there is also the question of whether color blindness is a disorder. [16]
While occupational therapists using a sensory integration frame of reference work on increasing a child's ability to adequately process sensory input, other OTs may focus on environmental accommodations that parents and school staff can use to enhance the child's function at home, school, and in the community.
ADHD medication tied to 19% lower death risk. An observational study conducted in Sweden, whose results appeared in JAMA in March 2024, further emphasized the positive impact of ADHD medication on ...
Attention deficit hyperactivity disorder (ADHD) [1] is a neurodevelopmental disorder characterized by symptoms of inattention, hyperactivity, impulsivity and emotional dysregulation that are excessive and pervasive, impairing in multiple contexts, and developmentally-inappropriate. [9]
Males are more likely to inherit red–green color blindness than females, because the genes for the relevant opsins are on the X chromosome. [1] Screening for congenital red–green color blindness is typically performed with the Ishihara or similar color vision test. [1] It is a lifelong condition, and has no known cure or treatment. [1]
Blue cone monochromacy (BCM) is an inherited eye disease that causes severe color blindness, poor visual acuity, nystagmus, hemeralopia, and photophobia due to the absence of functional red (L) and green (M) cone photoreceptor cells in the retina. BCM is a recessive X-linked disease and almost exclusively affects XY karyotypes.